+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States

Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States

Plos One 11(1): E0145977

This study (NCT01682005) aims to assess clinical and cost impacts of complete and incomplete rotavirus (RV) vaccination. Beneficiaries who continuously received medical and pharmacy benefits since birth were identified separately in Truven Commercial Claims and Encounters (2000-2011) and Truven Medicaid Claims (2002-2010) and observed until the first of end of insurance eligibility or five years. Infants with ≥1 RV vaccine within the vaccination window (6 weeks-8 months) were divided into completely and incompletely vaccinated cohorts. Historically unvaccinated (before 2007) and contemporarily unvaccinated (2007 and after) cohorts included children without RV vaccine. Claims with International Classification of Disease 9th edition (ICD-9) codes for diarrhea and RV were identified. First RV episode incidence, RV-related and diarrhea-related healthcare resource utilization after 8 months old were calculated and compared across groups. Poisson regressions were used to generate incidence rates with 95% confidence intervals (CIs). Mean total, inpatient, outpatient and emergency room costs for first RV and diarrhea episodes were calculated; bootstrapping was used to construct 95% CIs to evaluate cost differences. 1,069,485 Commercial and 515,557 Medicaid patients met inclusion criteria. Among commercially insured, RV incidence per 10,000 person-years was 3.3 (95% CI 2.8-3.9) for completely, 4.0 (95% CI 3.3-5.0) for incompletely vaccinated, and 20.9 (95% CI 19.5-22.4) for contemporarily and 40.3 (95% CI 38.6-42.1) for historically unvaccinated. Rates in Medicaid were 7.5 (95% CI 4.8-11.8) for completely, 9.0 (95% CI 6.5-12.3) for incompletely vaccinated, and 14.6 (95% CI 12.8-16.7) for contemporarily and 52.0 (95% CI 50.2-53.8) for historically unvaccinated. Mean cost for first RV episode per cohort member was $15.33 (95% CI $12.99-$18.03) and $4.26 ($95% CI $2.34-$6.35) lower for completely vaccinated versus contemporarily unvaccinated in Commercial and Medicaid, respectively. RV vaccination results in significant reduction in RV infection. There is evidence of indirect benefit to unvaccinated individuals.

(PDF emailed within 1 workday: $29.90)

Accession: 058661160

Download citation: RISBibTeXText

PMID: 26751375

Related references

Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine 35(37): 5065-5072, 2017

Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States. Human Vaccines and Immunotherapeutics 10(8): 2255-2266, 2015

Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States. Human Vaccines and Immunotherapeutics 10(7): 2032-2038, 2016

Rotavirus Vaccination Is Associated With Reduced Seizure Hospitalization Risk Among Commercially Insured US Children. Clinical Infectious Diseases 67(10): 1614-1616, 2018

Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015. Clinical Therapeutics 40(3): 430-439.E1, 2018

The Association Between Adherence to Antiretroviral Therapy and Economic Outcomes Among Commercially Insured and Medicaid HIV Patients in the United States. Value in Health 16(7): A348-A349, 2013

Updated Estimates of Ectopic Pregnancy among Commercially and Medicaid-Insured Women in the United States, 2002-2013. Southern Medical Journal 110(1): 18-24, 2017

Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States. Allergy and Asthma Proceedings 39(3): 201-211, 2018

Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007-2014. Vaccine 36(23): 3381-3386, 2018

Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States. Annals of PharmacoTherapy 50(12): 989-1000, 2016

Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. Pediatric Infectious Disease Journal 32(3): 278-283, 2013

Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. Journal of Managed Care and Specialty Pharmacy 24(11): 1156-1164, 2018

Adherence to rotavirus vaccination quality measures in a commercially insured population. Human Vaccines and Immunotherapeutics 9(2): 389-397, 2014

Trends in Opioid Prescription in Children and Adolescents in a Commercially Insured Population in the United States, 2004-2017. JAMA Pediatrics 2018, 2018

Impact Of Irritable Bowel Syndrome With Constipation On Work Productivity And Daily Activity Among Commercially Insured Patients In The United States. Value in Health 17(7): A370, 2014